Supplemental Table 4. Real-world time on treatment among patients with R/M HNSCC who received 1L combination platinum therapy

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | Second-line therapy | | |
|  |  | All patients  (N=391) | I-O monotherapy  (N=281) | Non-I-O therapy  (N=98) |
| Patient follow-up, months A |  | 5.7 (0.0 – 33.5) | 5.6 (0.0 – 33.4) | 7.6 (0.8 – 33.5) |
| Time on treatment, months B |  | 2.3 (2.1 - 2.8) | 2.8 (2.1 - 3.0) | 2.1 (1.7 - 2.4) |
| On-treatment rate C |  |  |  |  |
| 6 months |  | 19.1% (15.1 - 23.4) | 23.2% (18.2 – 28.7) | 6.49% (2.49 – 13.2) |
| 12 months |  | 12.2% (8.84 - 16.2) | 16.2% (11.7 - 21.4) | 1.30% (0.11 – 6.19) |
| 18 months |  | 7.93% (5.05 - 11.6) | 10.4% (6.53 - 15.2) | - |

I-O, immuno-oncology

A Patient follow-up was defined as time from second-line initiation to date of death or data cutoff, whichever occurred first. Values are presented as median (95% CI) months.

B Time on second-line therapy. Values are presented as median (95% CI). Based on the Kaplan-Meier time-to-event model.

C Values are presented as percent (95% CI). Based on the Kaplan-Meier time-to-event model.